Khondrion presents Phase II KHENERGY trial data

Published: 22 November 2017November 22, 2017 – FOR IMMEDIATE RELEASEKhondrion presents Phase II KHENERGY trial data. Data supporting Phase III development of KH176 in mitochondrial disease.NIJMEGEN, The Netherlands – Khondrion, a leading clinical-stage...

Khondrion will present first results of KHENERGY study

Published: 16 November 2017November 16, 2017 – FOR IMMEDIATE RELEASEKhondrion will present first results of KHENERGY studyResults of Phase 2 clinical trial with KH176 in adult mitochondrial disease patients will be presented at Dutch Life Sciences...

New Patents granted for KH176

New Patents granted for Khondrion’s mitochondrial disease lead compound KH176 NIJMEGEN, The Netherlands – Khondrion, a clinical-stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, announces today the grant of key patents in...